

PRESS RELEASE

to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism

Leiden, September 17th 2009

to-BBB, the Dutch brain drug delivery company, and MedImmune are starting a research program to evaluate to-BBB's proprietary G-Technology™ to safely deliver drugs to the brain.

Many brain diseases cannot be treated with today's disease modifying biologics due to the presence of the neuroprotective blood-brain barrier (BBB). to-BBB's promising G-Technology is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated liposomes. The G-Technology has shown proof of concept in different disease models for pain, viral encephalitis and brain tumors, based on which MedImmune will now evaluate the technology in its own pharmacodynamic models.

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.

"We are looking forward to working with MedImmune" says Pieter Gaillard, CSO of to-BBB "The project will be of great value to further validate our brain delivery platform and work towards therapies for devastating brain diseases".

About to-BBB

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for devastating brain disorders by combining existing drugs with its proprietary brain delivery platform. The company's vision is that the treatment of currently unserved, devastating brain diseases will be best achieved by safely enhancing blood-to-brain delivery of drugs.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

Contact

Willem van Weperen
Chief Executive Officer

Phone: +31 71 3322252
Mobile: +31 634 054812
E-mail: vanweperen@toBBB.com

to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com

Pieter Gaillard, PhD
Chief Scientific Officer

Phone: +31 71 3322251
Mobile: +31 621 525000
E-mail: gaillard@toBBB.com

to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com